Author’s response to reviews

Title: Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report

Authors:
Yuta Adachi (y.adachi@aichi-cc.jp)
Naohiro Yanagimura (nyanagimura@staff.kanazawa-u.ac.jp)
Chiaki Suzuki (csuzuki@staff.kanazawa-u.ac.jp)
Sakiko Ootani (sotani@staff.kanazawa-u.ac.jp)
Azusa Tanimoto (atanimoto@staff.kanazawa-u.ac.jp)
Akihiro Nishiyama (an0510@staff.kanazawa-u.ac.jp)
Kaname Yamashita (kanamey@staff.kanazawa-u.ac.jp)
Koushiro Ohtsubo (ohtsubo@staff.kanazawa-u.ac.jp)
Shinji Takeuchi (takeuchi@staff.kanazawa-u.ac.jp)
Seiji Yano (syano@staff.kanazawa-u.ac.jp)

Version: 2 Date: 07 Feb 2020

Author’s response to reviews:

William Spenceley Jones, Assistant Editor
BMC Cancer

February 7, 2020

Dear Dr. William Spenceley Jones:

Thank you for inviting us to submit a revised draft of our manuscript entitled, “Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report” to BMC cancer. We also appreciate the time and effort you and the reviewers have dedicated to providing a feedback on ways to strengthen our paper. Thus, it is with great pleasure that we resubmit our article for further consideration. We have incorporated changes that reflect the suggestions the editor have provided.

To facilitate your review of our revisions, the following is a point-by-point response to the questions and comments delivered in your letter.
Editor Comments

1. Please ensure that the email address for the corresponding author matches that which has been listed on our editorial system - currently they differ.

Because I’ve been transferred to another institution, the email address listed within our case report can no longer be available. I have changed the email address of the corresponding author.

2. Please confirm if a copy of the written consent form is available for the journal, and if so please include a statement to this effect in the 'Consent for Publication' section.

The copy of the written informed consent form is available. Therefore, I add the sentence.

3. We notice that author Sakiko Ootani is missing from the authors' contributions section. The individual contributions of each and all authors to the manuscript should be specified in the Authors’ Contributions section. Guidance and criteria for authorship can be found here:

We apologize that we failed to write the contributions of Sakiko Ootani for our case report. I have fixed the “Author’s Contributions”.

Reviewer 1
Comments to Author
Authors responded to my question sincerely. Thus, I have no additional comments.

Thank you very much for your comments which enable us to make our case report better.

Reviewer 2

GENERAL COMMENTS: The case report is mainly about optimal management of toxicities in NSCLC. The toxicity is rhabdomyolysis which is very rare but hard to manage because there is no known algorithm for the management. These cases managed case by case. This case report is very important because they report case by case management and more importantly report a rechallenge of the offending drug with reduced dose. Therefore, though it is a case report I strongly suggest that this knowledge 'rechallenge of the dabrafenib-trametinib' is very valuable knowledge.

REQUESTED REVISIONS: none

ADDITIONAL REQUESTS/SUGGESTIONS: the authors report management and rechallenge of the very rare and serious drug related toxicity in lethal tumor, which patient did not have any chance to treat with any other drug. Therefore, I think that this knowledge is very important and valuable to the literature.

Thank you very much for your comments. We believe this case report can help the physicians to make their clinical decisions.
Although within reviewer 2 comments, this case report needs some language corrections before being published, we can’t find any specific part we need to correct. This case report has already been reviewed by professional English language editing service. Therefore, we fix our case report as indicated by the editor. Again, thank you for giving us the opportunity to strengthen our manuscript. We hope that these revisions persuade you to accept our submission.

Sincerely yours,
Yuta Adachi, M.D., Ph.D.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University
13-1, Takara-machi, Kanazawa, Ishikawa 920-0934, Japan
TEL: +81-76-265-2794, FAX: +81-76-234-4524
e-mail: y.adachi@aichi-cc.jp